The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche

The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche

Bibliographic Details
Main Authors:	C Main, M Pitt, T Moxham, K Stein
Format:	Article
Language:	English
Published:	NIHR Journals Library 2010-10-01
Series:	Health Technology Assessment
Online Access:	https://doi.org/10.3310/hta14suppl2/04

Similar Items

Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia
by: J Dretzke, et al.
Published: (2010-10-01)

Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial
by: Dena R Howard, et al.
Published: (2017-05-01)

Role of rituximab in first-line treatment of chronic lymphocytic leukemia
by: Jeffrey Bryan, et al.
Published: (2010-12-01)

Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia
by: S Walker, et al.
Published: (2009-06-01)

Everolimus for the second-line treatment of advanced and/or metastatic renal cell cancer: a critique of the submission from Novartis
by: M Pitt, et al.
Published: (2010-10-01)

Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK
by: M Hoyle, et al.
Published: (2011-05-01)

Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis
by: K Dalziel, et al.
Published: (2004-07-01)

Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?
by: Lukáš Smolej, et al.
Published: (2021-06-01)

Prognostic role of CD4 T-cell depletion after frontline fludarabine, cyclophosphamide and rituximab in chronic lymphocytic leukaemia
by: Martin Gauthier, et al.
Published: (2019-08-01)

Simultaneous clinical resolution of focal segmental glomerulosclerosis associated with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab
by: Karasavvidou Foteini, et al.
Published: (2011-07-01)

Whipple's Disease as the First Manifestation of Chronic Lymphocytic Leukaemia
by: Verónica Botelho Guiomar, et al.
Published: (2019-09-01)

Thyroid nodule: first manifestation of chronic lymphocytic leukaemia
by: Ana Gonçalves, et al.

Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for treatment of chronic lymphocytic leukemia in Ukraine
by: Mandrik O, et al.
Published: (2015-08-01)

The cost-effectiveness of treatment of relapsed/refractory chronic lymphocytic leukemia with a combination of venetoclax and rituximab
by: Alla V Rudakova, et al.
Published: (2019-06-01)

Chromosome studies in familial leukaemia and chronic lymphocytic leukaemia
by: Fitzgerald, P. H.
Published: (2012)

HEMATOLOGICAL MALIGNANCIES. LYMPHOCYTIC LEUKAEMIA
by: Peter F. Litvitsky, et al.
Published: (2016-11-01)

Apoptosis in chronic lymphocytic leukaemia
by: King, Diane
Published: (2000)

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation.
by: G Rogers, et al.
Published: (2012-04-01)

The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review
by: R. Garside, et al.
Published: (2002-01-01)

Efficacy of a bendamustine and rituximab combination in first-line therapy for chronic lymphocytic leukemia: Results of the BEN-001 study
by: E A Stadnik, et al.
Published: (2017-07-01)

Effect of immunomodulatory agents on critical pathways in chronic lymphocytic leukaemia
by: Mondru, Anil Kumar
Published: (2018)

Cost-effectiveness Analysis of Rituximab Maintenance Treatment in Patients With Follicular Lymphoma who Respond to First Line Induction Therapy in Portugal
by: Susana Carvalho, et al.
Published: (2016-01-01)

The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis
by: Xingdi Hu, et al.
Published: (2019-12-01)

The role of the T lymphocyte in B cell chronic lymphocytic leukaemia
by: McCrea, Anthony Philip
Published: (1989)

Pharmacoeconomic analysis of the use of ibrutinib in therapy of the first line of a chronic lymphocytic leukaemia for patients with 17p deletion
by: A. S. Kolbin, et al.
Published: (2018-05-01)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain
by: Mareque M, et al.
Published: (2021-04-01)

Chronic lymphocytic leukaemia: An immunobiology approach
by: Kostareli Efterpi, et al.
Published: (2008-01-01)

An Unusual Presentation of Chronic Lymphocytic Leukaemia
by: Kavita Paul, et al.
Published: (2015-08-01)

Translational profiling of chronic lymphocytic leukaemia
by: Rogers, Helen
Published: (2005)

Concurrence of chronic lymphocytic leukaemia/small lymphocytic lymphoma and acute myeloid leukaemia in a bone marrow biopsy
by: Stefano Licci
Published: (2020-10-01)

The effect of game-based exercise on infant acute lymphocytic leukaemia patients
by: Édgar Cortés Reyes, et al.
Published: (2013-10-01)

Computerised decision support systems in order communication for diagnostic, screening or monitoring test ordering: systematic reviews of the effects and cost-effectiveness of systems
by: C Main, et al.
Published: (2010-10-01)

Cost-Effectiveness Analysis of Gemtuzumab Ozogamicin for First-Line Treatment of Patients with Cd-33 Positive Acute Myeloid Leukaemia in Spain [Corrigendum]
by: Mareque M, et al.
Published: (2021-07-01)

Rituximab for the treatment of patients with chronic lymphocytic leukemia
by: M Gentile, et al.
Published: (2010-03-01)

THE ON – LINE METHOD FOR THE SUBMISSION OF TAX DECLARATIONS
by: Mihai ANTONESCU, et al.
Published: (2010-03-01)

Acceptance of health technology assessment submissions with incremental cost-effectiveness ratios above the cost-effectiveness threshold
by: Griffiths EA, et al.
Published: (2015-08-01)

An investigation into the effects of metformin in combination with Clofarabine for the treatment of leukaemia using T-lymphoblastic leukaemia cell lines
by: Nemuvumoni, Ntakadzeni
Published: (2021)

Chronic lymphocytic leukaemia with concomitant plasmablastic lymphoma
by: Jacqueline Goedhals, et al.
Published: (2017-03-01)

An unusual presentation of Chronic Lymphocytic Leukaemia as delirium
by: N Manamohan, et al.
Published: (2017-01-01)

The expression and function of LCK in chronic lymphocytic leukaemia
by: Thompson, Victoria Joanne
Published: (2010)